PT  - JOURNAL ARTICLE
AU  - Trilla-Fuertes, Lucía
AU  - Ghanem, Ismael
AU  - Gámez-Pozo, Angelo
AU  - Maurel, Joan
AU  - G-Pastrián, Laura
AU  - Mendiola, Marta
AU  - Peña, Cristina
AU  - López-Vacas, Rocío
AU  - Prado-Vázquez, Guillermo
AU  - López-Camacho, Elena
AU  - Zapater-Moros, Andrea
AU  - Heredia, Victoria
AU  - Cuatrecasas, Miriam
AU  - García-Alfonso, Pilar
AU  - Capdevila, Jaume
AU  - Conill, Carles
AU  - García-Carbonero, Rocío
AU  - Ramos-Ruiz, Ricardo
AU  - Fortes, Claudia
AU  - Llorens, Carlos
AU  - Nanni, Paolo
AU  - Fresno Vara, Juan Ángel
AU  - Feliu, Jaime
TI  - Genetic profile and functional proteomics of anal squamous cell carcinoma: proposal for a molecular classification
AID  - 10.1101/19009522
DP  - 2019 Jan 01
TA  - medRxiv
PG  - 19009522
4099  - http://medrxiv.org/content/early/2019/10/18/19009522.short
4100  - http://medrxiv.org/content/early/2019/10/18/19009522.full
AB  - Background Anal squamous cell carcinoma is a rare tumor. Chemo-radiotherapy yields a 50% 3-year relapse-free survival rate in advanced anal cancer, so improved predictive markers and therapeutic options are needed.Methods High-throughput proteomics and whole-exome sequencing were performed in 46 paraffin samples from anal squamous cell carcinoma patients. Hierarchical clustering was used to establish groups de novo. Then, probabilistic graphical models were used to study the differences between groups of patients at the biological process level.Results A molecular classification into two groups of patients was established, one group with increased expression of proteins related to adhesion, T lymphocytes and glycolysis; and the other group with increased expression of proteins related to translation and ribosomes. The probabilistic graphical model showed that these two groups presented differences in metabolism, mitochondria, translation, splicing and adhesion processes. Additionally, these groups showed different frequencies of genetic variants in some genes, such as ATM, SLFN11 and DST. Finally, genetic and proteomic characteristics of these groups suggested the use of some possible targeted therapies, such as PARP inhibitors or immunotherapy.Conclusions In this study, a molecular classification of anal squamous cell carcinoma using high-throughput proteomics and whole-exome sequencing data was proposed. Moreover, differences between the two established groups suggested some possible therapies.Competing Interest StatementJAFV and AG-P are shareholders in Biomedica Molecular Medicine SL. LT-F and GP-V are employees of Biomedica Molecular Medicine SL. JC has received honoraria for scientific consulting (as speaker and advisory roles) from Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi and Merck Serono and research support from Eisai, Novartis, Ipsen, Astrazeneca, Pfizer and Advanced Accelerator Applications. IG has received honoraria and/or travel expenses from Roche, Sanofi, Merck, Servier, Amgen and Sirtflex, and for advisory role from Merck and Sanofi. JF has received consulting and advisory honoraria from Amgen, Ipsen, Eissai, Merck, Roche and Novartis; research funding from Merck, and travel and accommodation expenses from Amgen and Servier. The other authors declare no conflicts of interest.Funding StatementThis study was supported by the Instituto de Salud Carlos III, Spanish Economy and Competitiveness Ministry, Spain and co-sponsored by the FEDER program, “Una forma de hacer Europa” (PI15/01310), a Roche Farma grant, Cátedra UAM-Amgen and a grant of Grupo Español Multidisciplinar en Cáncer Digestivo (GEMCAD1403). LT-F is supported by the Spanish Economy and Competitiveness Ministry (DI-15-07614). GP-V is supported by the Consejería de Educación, Juventud y Deporte of Comunidad de Madrid (IND2017/BMD7783); AZ-M is supported by Jesús Antolín Garciarena fellowship from IdiPAZ. The sponsors were not involved in the study design, in data collection and analysis, in the decision to publish or in the preparation of this manuscript.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe proteomics data generated during the current study are available in Chorus repository (https://chorusproject.org/pages/index.html). The exome sequencing data are available in SRA https://www.ncbi.nlm.nih.gov/sra) under the name PRJNA573670. https://chorusproject.org/pages/index.html) https://www.ncbi.nlm.nih.gov/sra ASCCAnal squamous cell carcinoma5FU5-fluorouracilDFSdisease-free survivalWESwhole-exome sequencingMSmass-spectrometryPGMprobabilistic graphical modelFFPEformalin-fixed paraffin-embeddedECOG-PSEastern Cooperative Oncology Group performance statusHPVHuman papilloma virusVEPVariant Effect PredictorDDAData-dependent acquisitionFDRFalse Discovery RateFBAFlux Balance AnalysisBICBayesian Information CriterionGPRGene-Protein-Reaction rulesSAMSignificance Analysis of MicroarraysPARPiPARP inhibitors